Effect of Z-103 on TNB-induced colitis in rats.
Z-103 is a chelate compound consisting of zinc ion and L-carnosine. In this study, we investigated the protective effect of Z-103 against colonic damage induced by 2,4,6-trinitrobenzene sulfonic acid (TNB) in rats. Colonic inflammation was induced by administering TNB dissolved in 50% ethanol (120 mg/ml) in male Wistar rats (total volume of 0.25 ml per rat) following a 48-hour fast. After the administration of TNB, Z-103 was given at a dose of 30 mg/kg per rat for 1 week. A second group of rats received sulfasalazine (SASP) at 300 mg/kg and a third group of rats received 30 mg/kg of ZnSO4 for 1 week. Colonic inflammation was assessed 1 week following TNB administration. Both macro- and microscopic evaluation showed that the inflammatory responses induced by TNB were reduced by treatment with Z-103, SASP and ZnSO4. The score (graded from 0 to 5 according to the macroscopic lesions) and colonic wet weight (distal 8 cm of the colon) were significantly decreased by treatment with Z-103, SASP and ZnSO4. The increase in thiobarbituric acid-reactive substances in the colonic mucosa following TNB administration were inhibited in the Z-103 and SASP groups. These results suggest that Z-103 is as effective against TNB-induced colitis as SASP.
Yoshikawa
T
T
First Department of Medicine, Kyoto Prefectural University of Medicine, Japan.
Yamaguchi
T
T
Yoshida
N
N
Yamamoto
H
H
Kitazumi
S
S
Takahashi
S
S
Naito
Y
Y
Kondo
M
M
D000818:Animals; D000897:Anti-Ulcer Agents / Q000627:therapeutic use*; D000975:Antioxidants / Q000627:therapeutic use; D002336:Carnosine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D003092:Colitis / Q000139:chemically induced / Q000188:drug therapy* / Q000473:pathology; D003106:Colon / Q000473:pathology; D007413:Intestinal Mucosa / Q000473:pathology; D008297:Male; D009942:Organometallic Compounds / Q000627:therapeutic use*; D051381:Rats; D017208:Rats, Wistar; D012460:Sulfasalazine / Q000627:therapeutic use; D014302:Trinitrobenzenesulfonic Acid; D015032:Zinc / Q000627:therapeutic use*; D017967:Zinc Compounds; D019287:Zinc Sulfate / Q000627:therapeutic use
D000897:Anti-Ulcer Agents; D000975:Antioxidants; D009942:Organometallic Compounds; D017967:Zinc Compounds; C061957:polaprezinc; D012460:Sulfasalazine; D019287:Zinc Sulfate; D002336:Carnosine; D014302:Trinitrobenzenesulfonic Acid; D015032:Zinc